{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T03:51:46Z","timestamp":1781581906653,"version":"3.54.5"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,15]]},"DOI":"10.7759\/cureus.110928","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T02:55:23Z","timestamp":1781578523000},"source":"Crossref","is-referenced-by-count":0,"title":["Possible Diclofenac-Related Fulminant Toxic Epidermal Necrolysis: A Case Report"],"prefix":"10.7759","author":[{"given":"Natalia","family":"Quintero Serrano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga Luc\u00eda","family":"Melo Trujillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-5-39","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome","volume":"5","author":"Harr T","year":"2010","unstructured":"Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis. 2010, 5:39. 10.1186\/1750-1172-5-39","journal-title":"Orphanet J Rare Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.330","article-title":"TNF-\u03b1 and IFN-\u03b3 are potential inducers of Fas-mediated keratinocyte apoptosis through activation of inducible nitric oxide synthase in toxic epidermal necrolysis","volume":"133","author":"Viard-Leveugle I","year":"2013","unstructured":"Viard-Leveugle I, Gaide O, Jankovic D, et al.. TNF-\u03b1 and IFN-\u03b3 are potential inducers of Fas-mediated keratinocyte apoptosis through activation of inducible nitric oxide synthase in toxic epidermal necrolysis. J Invest Dermatol. 2013, 133:489-98. 10.1038\/jid.2012.330","journal-title":"J Invest Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s40267-018-0512-4","article-title":"Management and outcome of Stevens-Johnson syndrome and toxic epidermal necrolysis in patients admitted to Kenyatta National Hospital","volume":"34","author":"Irungu KK","year":"2018","unstructured":"Irungu KK, Nyamu DG, Opanga SA, et al.. Management and outcome of Stevens-Johnson syndrome and toxic epidermal necrolysis in patients admitted to Kenyatta National Hospital. Drugs Ther Perspect. 2018, 34:444-50. 10.1007\/s40267-018-0512-4","journal-title":"Drugs Ther Perspect"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14530","article-title":"U.K. guidelines for the management of Stevens-Johnson syndrome\/toxic epidermal necrolysis in adults 2016","volume":"174","author":"Creamer D","year":"2016","unstructured":"Creamer D, Walsh SA, Dziewulski P, et al.. U.K. guidelines for the management of Stevens-Johnson syndrome\/toxic epidermal necrolysis in adults 2016. Br J Dermatol. 2016, 174:1194-227. 10.1111\/bjd.14530","journal-title":"Br J Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study","volume":"128","author":"Mockenhaupt M","year":"2008","unstructured":"Mockenhaupt M, Viboud C, Dunant A, et al.. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 2008, 128:35-44. 10.1038\/sj.jid.5701033","journal-title":"J Invest Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-017-8654-z","article-title":"Current perspectives on Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"54","author":"Lerch M","year":"2018","unstructured":"Lerch M, Mainetti C, Terziroli Beretta-Piccoli B, Harr T. Current perspectives on Stevens-Johnson syndrome and toxic epidermal necrolysis. Clin Rev Allergy Immunol. 2018, 54:147-76. 10.1007\/s12016-017-8654-z","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2012.04.002","article-title":"Recent advances in the genetics and immunology of Stevens-Johnson syndrome and toxic epidermal necrosis","volume":"66","author":"Chung WH","year":"2012","unstructured":"Chung WH, Hung SI. Recent advances in the genetics and immunology of Stevens-Johnson syndrome and toxic epidermal necrosis. J Dermatol Sci. 2012, 66:190-6. 10.1016\/j.jdermsci.2012.04.002","journal-title":"J Dermatol Sci"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2025.05.002","article-title":"Updates in the pathogenesis of SJS\/TEN","volume":"74","author":"Justice J","year":"2025","unstructured":"Justice J, Mukherjee E, Martin-Pozo M, Phillips E. Updates in the pathogenesis of SJS\/TEN. Allergol Int. 2025, 74:361-71. 10.1016\/j.alit.2025.05.002","journal-title":"Allergol Int"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.05.003","article-title":"Toxic epidermal necrolysis: part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis","volume":"69","author":"Schwartz RA","year":"2013","unstructured":"Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. J Am Acad Dermatol. 2013, 69:173.e1-13. 10.1016\/j.jaad.2013.05.003","journal-title":"J Am Acad Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/s0041-008x(03)00368-5","article-title":"Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity","volume":"192","author":"Boelsterli UA","year":"2003","unstructured":"Boelsterli UA. Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Toxicol Appl Pharmacol. 2003, 192:307-22. 10.1016\/s0041-008x(03)00368-5","journal-title":"Toxicol Appl Pharmacol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2174\/1389200033489398","article-title":"The metabolism of diclofenac - enzymology and toxicology perspectives","volume":"4","author":"Tang W","year":"2003","unstructured":"Tang W. The metabolism of diclofenac - enzymology and toxicology perspectives. Curr Drug Metab. 2003, 4:319-29. 10.2174\/1389200033489398","journal-title":"Curr Drug Metab"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/s0300-483x(00)00397-8","article-title":"Metabolic activation in drug allergies","volume":"158","author":"Park BK","year":"2001","unstructured":"Park BK, Naisbitt DJ, Gordon SF, Kitteringham NR, Pirmohamed M. Metabolic activation in drug allergies. Toxicology. 2001, 158:11-23. 10.1016\/s0300-483x(00)00397-8","journal-title":"Toxicology"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.01847.x","article-title":"Adverse drug reactions: back to the future","volume":"55","author":"Pirmohamed M","year":"2003","unstructured":"Pirmohamed M, Park BK. Adverse drug reactions: back to the future. Br J Clin Pharmacol. 2003, 55:486-92. 10.1046\/j.1365-2125.2003.01847.x","journal-title":"Br J Clin Pharmacol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.7859","article-title":"Genetic variants associated with phenytoin-related severe cutaneous adverse reactions","volume":"312","author":"Chung WH","year":"2014","unstructured":"Chung WH, Chang WC, Lee YS, et al.. Genetic variants associated with phenytoin-related severe cutaneous adverse reactions. JAMA. 2014, 312:525-34. 10.1001\/jama.2014.7859","journal-title":"JAMA"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.832048","article-title":"Drug-induced severe cutaneous adverse reactions: insights into clinical presentation, immunopathogenesis, diagnostic methods, treatment, and pharmacogenomics","volume":"13","author":"Tempark T","year":"2022","unstructured":"Tempark T, John S, Rerknimitr P, Satapornpong P, Sukasem C. Drug-induced severe cutaneous adverse reactions: insights into clinical presentation, immunopathogenesis, diagnostic methods, treatment, and pharmacogenomics. Front Pharmacol. 2022, 13:832048. 10.3389\/fphar.2022.832048","journal-title":"Front Pharmacol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-015-0158-0","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: an update","volume":"16","author":"Dodiuk-Gad RP","year":"2015","unstructured":"Dodiuk-Gad RP, Chung WH, Valeyrie-Allanore L, Shear NH. Stevens-Johnson syndrome and toxic epidermal necrolysis: an update. Am J Clin Dermatol. 2015, 16:475-93. 10.1007\/s40257-015-0158-0","journal-title":"Am J Clin Dermatol"},{"key":"ref17","doi-asserted-by":"crossref","DOI":"10.1001\/archderm.1995.01690170041005","article-title":"Erythema multiforme with mucous membrane involvement and Stevens-Johnson syndrome are clinically different disorders with distinct causes","volume":"131","author":"Assier H","year":"1995","unstructured":"Assier H, Bastuji-Garin S, Revuz J, Roujeau JC. Erythema multiforme with mucous membrane involvement and Stevens-Johnson syndrome are clinically different disorders with distinct causes. Arch Dermatol. 1995, 131:539-43.","journal-title":"Arch Dermatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: a severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin S","year":"2000","unstructured":"Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000, 115:149-53. 10.1046\/j.1523-1747.2000.00061.x","journal-title":"J Invest Dermatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.136.3.323","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death?","volume":"136","author":"Garcia-Doval I","year":"2000","unstructured":"Garcia-Doval I, LeCleach L, Bocquet H, Otero XL, Roujeau JC. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death?. Arch Dermatol. 2000, 136:323-7. 10.1001\/archderm.136.3.323","journal-title":"Arch Dermatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.12747","article-title":"Severe drug-induced skin reactions: clinical features, diagnosis, etiology, and therapy","volume":"13","author":"Paulmann M","year":"2015","unstructured":"Paulmann M, Mockenhaupt M. Severe drug-induced skin reactions: clinical features, diagnosis, etiology, and therapy. J Dtsch Dermatol Ges. 2015, 13:625-45. 10.1111\/ddg.12747","journal-title":"J Dtsch Dermatol Ges"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/504390-possible-diclofenac-related-fulminant-toxic-epidermal-necrolysis-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T02:55:25Z","timestamp":1781578525000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/504390-possible-diclofenac-related-fulminant-toxic-epidermal-necrolysis-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.110928","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,15]]}}}